{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:01:41Z","timestamp":1792450901326,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02328-8","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T01:12:59Z","timestamp":1779066779000},"page":"1165-1170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Narsoplimab: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-7391","authenticated-orcid":false,"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"3","key":"2328_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"ML Schoettler","year":"2023","unstructured":"Schoettler ML, Carreras E, Cho B, et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023;29(3):151\u201363.","journal-title":"Transplant Cell Ther."},{"key":"2328_CR2","unstructured":"US FDA. YARTEMLEA (narsoplimab-wuug) injection, for intravenous use. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761152Orig1s000lbl.pdf. Accessed 15 Apr 2026"},{"key":"2328_CR3","doi-asserted-by":"publisher","first-page":"1297352","DOI":"10.3389\/fimmu.2023.1297352","volume":"14","author":"T Dudler","year":"2023","unstructured":"Dudler T, Yaseen S, Cummings WJ. Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders. Front Immunol. 2023;14:1297352.","journal-title":"Front Immunol"},{"key":"2328_CR4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3389\/fimmu.2018.01851","volume":"9","author":"J Dob\u00f3","year":"2018","unstructured":"Dob\u00f3 J, Kocsis A, G\u00e1l P. Be on target: strategies of targeting alternative and lectin pathway components in complement-mediated diseases. Front Immunol. 2018;9:1851.","journal-title":"Front Immunol"},{"issue":"1","key":"2328_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cei.13497","volume":"203","author":"S Elhadad","year":"2021","unstructured":"Elhadad S, Chapin J, Copertino D, et al. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2021;203(1):96\u2013104.","journal-title":"Clin Exp Immunol"},{"key":"2328_CR6","unstructured":"US FDA. FDA approves first drug to treat serious complication of stem cell transplant [media release]. 05 Jan 2026. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-drug-treat-serious-complication-stem-cell-transplant."},{"key":"2328_CR7","unstructured":"Omeros Corporation. FDA approves Omeros\u2019 YARTEMLEA\u00ae \u2013 first and only therapy indicated for TA-TMA [media release]. 24 Dec 2025. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/fda-approves-omeros-yartemlear-first-and-only-therapy-indicated."},{"key":"2328_CR8","unstructured":"Omeros Corporation. Omeros Corporation reports second quarter 2025 financial results [media release]. 14 Aug 2025. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-reports-second-quarter-2025-financial-results."},{"issue":"6","key":"2328_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imbio.2020.152001","volume":"225","author":"A Rambaldi","year":"2020","unstructured":"Rambaldi A, Gritti G, Mic\u00f2 MC, et al. Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020;225(6):1\u201310.","journal-title":"Immunobiology"},{"issue":"1","key":"2328_CR10","first-page":"24","volume":"2","author":"MD Knierman","year":"2021","unstructured":"Knierman MD, Gelfanova V, Zlatniski NA, et al. Severe SARS-CoV-2 infection treated with the mannose binding lectin associated serine protease 2 (MASP2) inhibitor Narsoplimab. J Allergy Infect Dis. 2021;2(1):24\u20138.","journal-title":"J Allergy Infect Dis."},{"key":"2328_CR11","unstructured":"Omeros Corporation. Omeros selects clinical candidate for MASP-2 program with potential applicability to multiple inflammatory disorders [media release]. 13 May 2010. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-selects-clinical-candidate-masp-2-program-potential."},{"key":"2328_CR12","unstructured":"Omeros Corporation. Affitech and Omeros enter into antibody discovery and development agreement [media release]. 19 Aug 2008. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/affitech-and-omeros-enter-antibody-discovery-and-development."},{"key":"2328_CR13","unstructured":"Omeros Corporation. Form 10-K filed fiscal year ended December 31, 2009. 2010. https:\/\/investor.omeros.com\/static-files\/90d09dda-97fd-4c51-a8e2-bc0e6e6a64b0. Accessed 15 Apr 2026"},{"key":"2328_CR14","unstructured":"Omeros Corporation. Omeros announces research collaboration with University of Cambridge [media release]. 11 Dec 2018. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-announces-research-collaboration-university-cambridge."},{"key":"2328_CR15","unstructured":"Omeros Corporation. Omeros and Lonza enter long-term manufacturing agreement for commercial supply of narsoplimab [media release]. 31 Jul 2019. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-and-lonza-enter-long-term-manufacturing-agreement."},{"key":"2328_CR16","unstructured":"Omeros Corporation. myTomorrows and Omeros Corporation collaborate to provide an expanded access program for narsoplimab [media release]. 18 Dec 2019. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/mytomorrows-and-omeros-corporation-collaborate-provide-expanded."},{"key":"2328_CR17","unstructured":"Omeros Corporation. 2024 Annual Report. 2025. https:\/\/investor.omeros.com\/static-files\/7f29bc15-45ee-4b9e-a02c-54253f2154d0. Accessed 15 Apr 2026."},{"issue":"2","key":"2328_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/cei\/uxad055","volume":"213","author":"S Elhadad","year":"2023","unstructured":"Elhadad S, Redmond D, Huang J, et al. MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence. Clin Exp Immunol. 2023;213(2):252\u201364.","journal-title":"Clin Exp Immunol"},{"issue":"22","key":"2328_CR19","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1200\/JCO.21.02389","volume":"40","author":"SK Khaled","year":"2022","unstructured":"Khaled SK, Claes K, Goh YT, et al. Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy. J Clin Oncol. 2022;40(22):2447\u201357.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2328_CR20","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","volume":"90","author":"BS Cho","year":"2010","unstructured":"Cho BS, Yahng SA, Lee SE, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90(8):918\u201326.","journal-title":"Transplantation"},{"issue":"11","key":"2328_CR21","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/ajh.70044","volume":"100","author":"ML Schoettler","year":"2025","unstructured":"Schoettler ML, Pusarla SK, Nangia N, et al. Narsoplimab results in excellent survival in adults and children with hematopoietic cell transplant associated thrombotic microangiopathy (TA-TMA). Am J Hematol. 2025;100(11):2040\u201351.","journal-title":"Am J Hematol"},{"issue":"1","key":"2328_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/bloodadvances.2025017540","volume":"10","author":"H Matsui","year":"2026","unstructured":"Matsui H, Arai Y, Kanda J, et al. Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care. Blood Adv. 2026;10(1):111\u201320.","journal-title":"Blood Adv"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02328-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02328-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02328-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:39:41Z","timestamp":1782196781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02328-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2328"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02328-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}